

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently amended) A method for the treatment of renal cell cancer comprising co-administering an anti-tumor antibody directed against the MN antigen, wherein said antitumor antibody is a chimeric or humanized G250 antibody or a fragment thereof and a cytokine to a subject in need thereof, wherein the cytokine ~~consists of an interferon~~ is IFN- α and is administered continuously or repeatedly in a low-dose form, wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the absence of NIC CTC toxicity grade 3 or higher.
2. (Previously presented) A method for the treatment of renal cell cancer comprising co-administering an anti-tumor antibody directed against the MN antigen and cytokine to a subject in need thereof, wherein the cytokine consists of an interferon and the method comprises:
 - (a) a first treatment stage comprising administering a low-dose cytokine, and
 - (b) a second treatment stage comprising co-administering the anti-tumor antibody and a low-dose cytokine, and wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the absence of NIC CTC toxicity grade 3 or higher.
3. (Cancelled)

4. (Previously Presented) The method according to claim 1 comprising a daily administration of a low-dose cytokine.
- 5-7. (Cancelled)
8. (Canceled)
9. (Currently amended) The method of claim 8 1, wherein the dose of IFN- α is in the range of from 1-10 MIU three times a week.
10. (Previously Presented) The method of claim 1 wherein the cytokine is administered in a constant dose during the treatment.
11. (Canceled)
12. (Previously Presented) The method of claim 1 wherein the cytokine is administered subcutaneously.
13. (Cancelled)
14. (Canceled)

15. (Previously Presented) The method of claim 1 wherein the antitumor antibody is administered in intervals of from 5-20 days.
16. (Original) The method of claim 2 wherein the first treatment stage comprises 5-20 days.
17. (Original) The method of claim 2 wherein the second treatment stage comprises 50-200 days.
18. (Previously Presented) A method for the treatment of renal cell cancer comprising co-administering an anti-tumor antibody G250 or a fragment thereof and a cytokine IFN- α to a subject in need thereof, wherein the cytokine is administered continuously or repeatedly in a low-dose form, wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the absence of NIC CTC toxicity grade 3 or higher.
19. (New) A method for the treatment of renal cell cancer consisting essentially of co-administering an anti-tumor antibody directed against the MN antigen, wherein said antitumor antibody is a chimeric or humanized G250 antibody or a fragment thereof and a cytokine to a subject in need thereof, wherein the cytokine is IFN- α and is administered continuously or repeatedly in a low-dose form, wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the absence of NIC CTC toxicity grade 3 or higher.